Creating a new therapy to target harmful tau proteins in Alzheimer's disease
Development and Validation of a Novel Anti-Pathogenic Tau Conformation (TNT2) scFv Immuno-Gene Therapy
This study is testing a new gene therapy that uses a special treatment to target harmful tau proteins in the brains of people with Alzheimer's and similar conditions, aiming to deliver help directly to the affected brain cells for better results than current treatments.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health + Michigan State University Health Sciences NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-10904209 on NIH RePORTER |
What this research studies
This research focuses on developing a novel gene therapy that targets specific harmful forms of tau proteins associated with Alzheimer's disease and related dementias. By using a specially designed antibody fragment, the therapy aims to deliver treatment directly into affected neurons, addressing the root causes of toxicity. The approach utilizes recombinant adeno-associated viruses to ensure that the therapeutic agents reach the right location within the brain cells. This method is expected to improve the effectiveness of treatment compared to existing therapies that may not target the right forms of tau.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or related tauopathies who may benefit from targeted therapies.
Not a fit: Patients with non-tau related forms of dementia or those who do not have Alzheimer's disease may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for Alzheimer's disease, potentially slowing disease progression and improving patient outcomes.
How similar studies have performed: While there are ongoing studies exploring anti-tau therapies, this specific approach using gene therapy and targeted antibody delivery is relatively novel and has not been extensively tested.
Where this research is happening
East Lansing, United States
- Henry Ford Health + Michigan State University Health Sciences — East Lansing, United States (Active)
Researchers
- Principal investigator: Kanaan, Nicholas M — Henry Ford Health + Michigan State University Health Sciences
- Study coordinator: Kanaan, Nicholas M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.